AT A GLANCE

CHALLENGES DRIVING NEW VISIONS

With a strong development platform and four production sites, AMEGA Biotech develops and produces biosimilars. Exporting recombinant proteins worldwide and focused on central markets registrations, AMEGA Biotech is the leading regional producer.
Our work and vision are directed forward. Our production model is based on a comprehensive design and integration of all the processes involved in the production of high quality and high technology products. This competitive advantage allows us to face the present and future challenges of a dynamic field.
We contribute to the future of biotechnology by understanding its high impact on society and its benefits on human health.

A NEW VISION

AMEGA Biotech is a biotechnology organization with a new vision on the production and commercialization of human biopharmaceuticals aimed at achieving the highest quality standards.

With a focus on competitiveness and time-to-market, the structure of AMEGA Biotech allows control of all the manufacturing processes, from the Active Pharmaceutical Ingredient (API) to the Finished Dosage Form.

AMEGA BIOTECH CORPORATE PRESENTATION


GLOBAL PRESENCE

This new vision enables AMEGA Biotech to access markets such as Latin America, MENA, Turkey, Southeast Asia, Russia, Ukraine.

MISSION STATEMENT

EXCELLENCE
FOR A BETTER FUTURE

We want to go beyond boarders by developing, producing and comercializing high-quality and first-to-market biosimilars to palliate and or cure significant human medical diseases.
We believe that biotechnology is a key industry for the growth and development of communities as well as for improving people’s quality of lives.

OUR VALUES

The AMEGA biotech project adheres to a set of core values that guide our actions as a company and our relationships with employees, partners, customers and the community.


1. Excellence

We are committed to the highest levels of scientic excellence through continuous investment in advanced scientic technologies and professional training, creating networks that encourage new insights and ideas.

2. Innovation

Innovation drives all our activities, from development to production and business development actions. We have an attitude towards the novel and the better behind every stage of the process.

3. Collaboration

We believe that successful results depend on team feedback and mutual enrichment. We promote collaboration at all levels as a platform for ensuring patients, partners, staff and shareholders an inclusive and thorough outcome.

4. Integrity

We hold ourselves to the highest of ethical principles in all aspects of our business. We carry out our work focusing on quality and showing a high degree of transparency in our dealings with competitors, customers, partners and institutions.
From individual behavior to corporate actions, we base our performance in mutual trust and responsibility. We act as we think and we reflect what we believe.

5. Flexibility

We share and profess the capacity to adapt to changing business and regulatory environments, both locally and internationally. Flexibility is also reflected in the continuous expansion of manufacturing capacities.

6. Quality

Quality Assurance is based on a system of standardized procedures to which every employee adheres to. We are focused on developing and exercising a quality policy with established quality objectives that are permanently reviewed.

7. Responsibility

We are aware of the impact that any human action, whether as individuals or as a company, has on the wellbeing of communities and we commit ourselves to the economical, social and environmental development of the areas affected by our activities.

FULL PROCESS CONTROL

INTEGRATED VALUE CHAIN,
GUARANTEE OF
THE HIGHEST QUALITY

AMEGA Biotech has fully integrated its development and production operations, controlling the process all the way from clone selection to the production of the purified protein and the formulation of the finished product. This advantage allows our organization to offer its customers added value through our integrated value chain, with the guarantee of the origin and consistent quality of its products.

Development

  • Development, production, purication, characterization and testing of a broad range of recombinant products.
  • Generation of Master Cell Bank and Working Cell Bank.
  • Development of technologies for sustained-release biopharmaceuticals.
  • Development of monoclonal antibodies.

Production

  • High-end internationally-audited production sites.

Fill-Finishing

  • Established network of partners with cGMP approved facilities allowing access to world markets.
  • Guaranteed fill-finishing quality.

Promotion And Distribution

  • Access to world markets through strategic alliances with local distributors.
  • Careful selection of potential distributors to create long standing partnerships.
  • Marketing support.

Our organization has set precedent for a dynamic development model that is able to control all the processes in the biopharmaceutical production chain as well as quality assurance, from the Active Pharmaceutical Ingredient (API) to the Finished Dosage Form (FDF).

WELCOME TO AMEGA BIOTECH SITES


OUR PEOPLE

TALENT THAT DRIVES
PROGRESS

We firmly believe that our people are the most important asset and guarantee for the successful achievements of our goals.

AMEGA Biotech combines the best-qualied professionals and scientists in the field and designs skillful and creative working teams that share our vision and values. This highly qualied resource is the key engine in our contribution to biotechnology and in our pursuit of improving people’s quality of life.

Our team includes experienced scientists, many of which are bearing PhD degrees. Their solid trajectory certies the expertise in a broad range of cell cultures such as CHO, E-coli, BHK and yeast cells.

Excellence, innovation, collaboration, integrity, flexibility, quality and responsability are the values that guide not only our actions as an organization, but also the relationship with our employees, partners, clients and the community.